16 Dec Sygnature Discovery invests £3m to expand high-throughput screening and translational oncology capabilities
Sygnature invests in new capabilities at two of its laboratories. • Automated sample storage for multi-customer, multi-year storage HTS relationships • Flow cytometry at Alderley Park to support ex vivo and in vivo tumour analysis BioCity based Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical...